Results 201 to 210 of about 1,572,967 (270)

The diagnostic value of the circadian rhythm gene KLF10 in anxiety‐depressive disorders and its neuroimmune regulatory mechanisms

open access: yesAnimal Models and Experimental Medicine, EarlyView.
This graphical abstract illustrates the protective role and molecular mechanism of the circadian rhythm‐related gene KLF10, identified as a diagnostic biomarker and therapeutic target in anxiety‐depressive disorder. Model establishment and phenotypes: An anxiety‐depression model was successfully established by chronic restraint stress combined with ...
Anlan Liu   +4 more
wiley   +1 more source

Baseline podocyte‐associated state and persistent cell–matrix transcriptional programs are associated with BALB/c substrain differences in adriamycin nephropathy

open access: yesAnimal Models and Experimental Medicine, EarlyView.
Two closely related BALB/c substrains exhibit different early responses to adriamycin (ADR)‐induced nephropathy. BALB/cByJcl mice showed lower baseline WT1‐positive nuclei counts and NPHS1 immunoreactivity than BALB/cAJcl mice, together with extracellular matrix and integrin programs that were enriched at baseline and persisted at Day 5.
Ryuya Nakagawa   +5 more
wiley   +1 more source

Neurotransmitter‐Defined Degeneration Patterns in Sporadic and C9orf72‐Associated Amyotrophic Lateral Sclerosis: Predilection to GABAergic, Serotonergic, Opioid, Glutamatergic, Endocannabinoid, and Microglial Systems—Implications for Therapy Development

open access: yesAnnals of Neurology, EarlyView.
Objective Amyotrophic lateral sclerosis (ALS) has a markedly distinctive clinical and neuroradiological signature, with the preferential involvement of specific brain networks and the apparent sparing of others. The molecular underpinnings of the strikingly selective anatomical vulnerability have not been fully elucidated to date despite the potential ...
Marlene Tahedl   +10 more
wiley   +1 more source

A decade of hair-loss clinical trials: a registry-based analysis of studies registered on ClinicalTrials.gov. [PDF]

open access: yesFront Med (Lausanne)
Parra-Guerra AD   +9 more
europepmc   +1 more source

Blood SOD1 Activity in ALS Patients Receiving Tofersen Treatment

open access: yesAnnals of Neurology, EarlyView.
Objective The antisense oligonucleotide tofersen is the first disease‐modifying drug for SOD1‐related amyotrophic lateral sclerosis (ALS) and was approved because of its ability to reduce SOD1 protein and neurofilament levels. The effect of tofersen on SOD1 activity is unclear but of clinical relevance because homozygous SOD1 mutations, linked to ...
Katharina Goehring   +18 more
wiley   +1 more source

Home - About - Disclaimer - Privacy